TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03115983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimiFlex
Description: LimiFlex implantation at a single level after surgical decompression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion Instrumentation
Description: Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Surgical decompression at one or two contiguous levels from L1 to S1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression
Description: Surgical decompression at one or two contiguous levels from L1 to S1.
Study: NCT03386097

Intervention type: OTHER
Intervention: Collection of interstitial fluid, skin biopsies and blood
Description: Collection of interstitial fluid, skin biopsies and blood

Intervention type: OTHER
Intervention: Collection of interstitial fluid, skin biopsies and blood
Description: Collection of interstitial fluid, skin biopsies and blood
Study: NCT01934374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-Oriented Lower Extremity Strengthening Training
Description: On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
Study: NCT03890250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic exercise
Description: A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds
Study: NCT03091166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study: NCT02523365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: interventional therapy
Description: cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study: NCT04780503

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Shallow Breathing Index
Description: The RSBI is defined as the ratio of respiratory frequency to tidal volume.

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Shallow Breathing Index
Description: The RSBI is defined as the ratio of respiratory frequency to tidal volume.
Study: NCT00824460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25 g PA21 (250 mg iron)
Description: Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5.0 g PA21 (1,000 mg iron)
Description: Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5 g PA21 (1,500 mg iron)
Description: Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10.0 g PA21 (2,000 mg iron)
Description: Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 g PA21 (2,500 mg iron)
Description: Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Description: Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Study: NCT03982849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone 4% Cream
Description: Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
Study: NCT02882217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XC8 (histamine glutarimide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XC8 (histamine glutarimide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XC8 (histamine glutarimide)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03982849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silymarin 0.7% cream
Description: Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
Study: NCT03115983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion
Description: Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
Study: NCT00175825

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
Study: NCT03952858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Group
Description: The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
Study: NCT02030015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
Study: NCT00977353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20-60 mg/day, oral, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarcosine
Description: 500-1500 mg/day, oral, for 6 weeks
Study: NCT03149432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
Study: NCT00522288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Description: Daily wear soft contact lenses disposed of daily or biweekly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle
Description: Spectacles for the treatment of myopia
Study: NCT03399422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: i-PRF (injectable platelet rich fibrin) assisted upper canine retraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: canine retraction
Description: upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: canine retraction
Description: upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
Study: NCT00728468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
Study: NCT02224768

Intervention type: DRUG
Intervention: Ipilimumab
Study: NCT01541462

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weaning
Description: Decrease assistance provided by the ventilator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weaning
Description: Decrease assistance provided by the ventilator
Study: NCT00990834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 80 mg PO daily for one to eight months.
Study: NCT01258608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
Study: NCT03149432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
Study: NCT01258608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
Study: NCT03248102

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blowing into the mouthpiece
Description: Blowing into the mouthpiece of diagnostic device
Study: NCT01719835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m2 IV every 21 days
Study: NCT03183466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic debridement
Study: NCT00000372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05101499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AKIN osteotomy with screw fixation
Description: A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AKIN osteotomy without screw fixation
Description: This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
Study: NCT04473079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacidofil
Description: Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
Study: NCT00593996

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol (vitamin D2)
Description: 50,000 IU 3 times weekly for 4 weeks
Study: NCT03605615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vocalization
Description: The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
Study: NCT03824210

Intervention type: OTHER
Intervention: App
Description: Mobile phone app

Intervention type: OTHER
Intervention: App
Description: Mobile phone app
Study: NCT03848585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pilloxa Pillbox
Description: A Pilloxa Pillbox is used for the prescribed immunosuppressants.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non active Pilloxa Pillbox
Description: A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
Study: NCT00062309

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT01719835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV Days 1, 8, 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m2 IV every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m2 (max 2mg) IV every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 100mg PO Days 1-5 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 1000mg oral or IV Days 1-5 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m2 IV Day 15 every 28 days
Study: NCT01297231

Intervention type: OTHER
Intervention: MRI
Description: Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~* Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~* Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~* Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated.
Study: NCT02070055

Intervention type: OTHER
Intervention: No intervention
Study: NCT04354467

Intervention type: DIAGNOSTIC_TEST
Intervention: urine neutrophil gelatinase -associated lipocalin
Description: urine biomarker is measured and batched procesessed
Study: NCT03853668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
Study: NCT01140217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate
Description: Norethindrone Acetate Transdermal Delivery System
Study: NCT02319811

Intervention type: PROCEDURE
Intervention: Cryopreserved meniscus transplants
Description: Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
Study: NCT04710810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: umbilical cord blood mononuclear stem cells
Description: UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.
Study: NCT02538731

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dilation-assisted stone extraction

Intervention type: DEVICE
Group type: OTHER
Intervention: Spyglass Guided Laser Lithotrips
Study: NCT00745745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Implantation
Description: ICD lead implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Implantation
Description: ICD lead implantation
Study: NCT01235390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: The consumption of assigned walnuts once a day during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: The consumption of assigned walnuts once a day during 4 weeks
Study: NCT01744522

Intervention type: PROCEDURE
Intervention: Leech therapy
Description: Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
Study: NCT03149432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local care
Description: local care for directed healing of the stump.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local care
Description: local care for directed healing of the stump.
Study: NCT00729508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 2X 4 administrations 2 weeks apart
Study: NCT01093118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMI-358
Description: Micro implant monthly x 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMI-467
Description: Micro implant monthly x 3
Study: NCT04098939

Intervention type: DIAGNOSTIC_TEST
Intervention: Diaphragm evaluation
Description: Ultrasound and radiographic evaluation of diaphragm function
Study: NCT05924542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kelaa Mental Resilience App
Description: Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change.
Study: NCT01580072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-monitoring for patients with severe COPD
Description: Intervention Group entering vital parameters via Web Portal or automatic call center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-monitoring for patients with severe COPD
Description: Nurses are entering vital parameters of the patient with mobile devices.